Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory Pemphigus vulgaris: report of a case.

作者： Luigi Virgolini , Vanda Marzocchi

关键词:

摘要:

参考文章(4)

Barbara Boughton, Rituximab for BCL-2-positive cancers. Lancet Oncology. ,vol. 4, pp. 69- ,(2003) , 10.1016/S1470-2045(03)00998-7

Francesco Zaja, Salvatore De Vita, Cesare Mazzaro, Stefania Sacco, Daniela Damiani, Ginevra De Marchi, Angela Michelutti, Michele Baccarani, Renato Fanin, Gianfranco Ferraccioli, Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. ,vol. 101, pp. 3827- 3834 ,(2003) , 10.1182/BLOOD-2002-09-2856

G. Herrmann, A. Engert, N. Hunzelmann, Treatment of pemphigus vulgaris with anti‐CD20 monoclonal antibody (rituximab) British Journal of Dermatology. ,vol. 148, pp. 602- 603 ,(2003) , 10.1046/J.1365-2133.2003.05209_10.X

Allen N. Sapadin, Michael J. Fellner, Current therapy of pemphigus vulgaris. Mount Sinai Journal of Medicine. ,vol. 68, pp. 268- 278 ,(2001)